International Journal of Pediatrics Research

Objective To explore the value of detection of Mycoplasma pneumoniae antibody and hypersensitive C-reactive protein in the diagnosis and treatment of pediatric pneumonia. Methods 50 children with mycoplasma pneumonia who were admitted to our hospital for treatment between March 2021 and March 2022 were randomly selected as the study object, and 50 healthy children were selected as the control group. The two groups of children were tested for mycoplasma pneumoniae antibody and hypersensitive C-reactive protein, so as to analyze their clinical application value. Results It was found that 54% of the children in the observation group had Mycoplasma antibody titer ratio of more than 1:40, while 2% in the control group, which was significantly higher than that in the observation group. Compared with the control group, the positive rate of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein in the observation group was significantly higher than that in the control group (P<0.05). In addition, the combined test of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein was significantly higher in the sensitivity, positive predictive value, negative predictive value and other indicators of mycoplasma pneumoniae pneumonia in children compared with the single test. The difference was significant (P<0.05). Conclusion In the process of clinical diagnosis of mycoplasma pneumoniae pneumonia in children, the combined test of mycoplasma pneumoniae antibody and hypersensitive C-reactive protein has better application effect and positive rate, which is worthy of being vigorously promoted in clinical practice.

Mycoplasma pneumoniae antibody in children; High sensitivity C-reactive protein test; Infantile pneumonia